AllSci News
Boehringer Ingelheim, Simcere partner to advance dual-target antibody for IBD
Germany’s Boehringer Ingelheim and China-based Simcere Pharmaceutical Group unveiled a license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody targeting…
VectorY Therapeutics’ VTx-002 gene therapy enters Phase I/II ALS trial
Netherlands-based VectorY Therapeutics has initiated a first-in-human clinical trial of VTx-002, an investigational gene therapy targeting amyotrophic lateral sclerosis (ALS) in a…
Fortitude Bio launches with USD 13m for next-gen glue-ADC combos
Fortitude Biomedicines, a new biopharmaceutical company headquartered in Waltham, Massachusetts, launched with USD 13 million in seed financing. The biotech is built…
Akari seeking patent for second ADC program targeting CEACAM5
Akari Therapeutics Plc announced the filing of a US provisional patent (No. 63/958,508) covering its second antibody-drug conjugate (ADC) program, AKTX-102, which…
Sarepta’s Elevidys continues recovery path with more positive data in Duchenne
Sarepta Therapeutics announced positive three-year results for Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). The news…
BioCryst closes USD 700m Astria Therapeutics acquisition for HAE pipeline
BioCryst Pharmaceuticals Inc., announced that its acquisition of Astria Therapeutics Inc., has closed, a transaction valued at approximately USD 700 million. BioCryst…
TPD3310: First-in-Human Phase I Trial Targeting c-MET Protein Degradation in Solid Tumors
Novel c-MET Degrader Enters First-in-Human Trial for Advanced Solid Tumors Researchers have initiat...
Genomics pioneer J. Craig Venter launches Diploid Genomics with Healthier Capital backing
Genomics pioneer J. Craig Venter, Ph.D., announced the launch of Diploid Genomics, Inc. (DGI), a new advanced genomics analytics company designed to…
Eisai, Biogen file with US FDA to add subcutaneous Leqembi formulation
The US FDA has accepted a supplemental Biologics License Application (sBLA) from Eisai and Biogen for a weekly subcutaneous starting dose of…
SPR1020: First-in-Human Phase I Trial Explores Highly Selective PARP1 Inhibitor Potential
A first-in-human clinical trial for SPR1020, a novel highly selective PARP1 inhibitor targeting advanced solid tumors, is set to begin, marking a potentially significant advance in precision oncology therapeutics. The phase I trial will evaluate the safety, tolerability, and preliminary efficacy of this new molecular entity designed to overcome limitations of current PARP inhibition strategies.
Shanghai Xianwei's SIM0610: First-in-Human Phase 1 Trial for Advanced Solid Tumors
Novel Cancer Therapeutic SIM0610 Enters First-in-Human Trial Shanghai Xianwei Medical Technology Co...
Veltischev Institute Launches First-in-Human ASO-GNAO1 Trial for Rare Neurological Disorder
Personalized Antisense Therapy Offers New Hope for Rare Neurological Disorder Researchers are launch...
Adcendo's ADCE-B05 ADC Enters Phase 1a/1b Trial for Advanced Solid Tumor Treatment
Novel Antibody-Drug Conjugate Enters First-in-Human Trial for Advanced Solid Tumors Adcendo ApS is a...
SWA1211 HPK1 Inhibitor Enters First-in-Human Phase I Trial for Advanced Solid Tumors
Novel HPK1 Inhibitor Enters First-in-Human Trial for Advanced Solid Tumors Researchers have initiat...
Corcept’s relacorilant adds OS endpoint in pivotal ROSELLA trial for ovarian cancer
Corcept Therapeutics reported positive data from the pivotal Phase III ROSELLA trial assessing relacorilant in combination with nab-paclitaxel in platinum-resistant ovarian cancer…
The AllSci Brief
Free, systematic R&D and deal news. Daily.